Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
26 Août 2024 - 10:30PM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today published an article in Molecular Therapy
demonstrating TALEN®-mediated gene editing capabilities for design
of SMART DUAL CAR T-cells, which efficiently target immunotherapy
recalcitrant solid tumors while mitigating potential safety risks.
Adoptive cell therapy based on CAR T cells has
proven to be lifesaving for many cancer patients. However, its
therapeutic efficacy has so far been restricted to only a few
malignancies, with solid tumors proving to be especially
recalcitrant to efficient therapy.
One key factor for this are cancer-associated
fibroblasts (CAFs), that modulate the tumor microenvironment (TME)
to inhibit T cell infiltration and induce T cell dysfunction.
Additionally, the sparsity of tumor-specific antigens (TSA) and
expression of CAR-directed tumor-associated antigens (TAA) on
normal tissues often results in on-target off-tumor cytotoxicity,
raising safety concerns.
Using TALEN® gene editing technology, Cellectis
presents an innovative CAR T cell engineering strategy designed to
overcome these challenges. Our allogeneic SMART CAR T-cells are
designed to express a constitutive CAR, targeting FAP+ CAFs in
solid tumors, and a second inducible CAR, expressed only in the
presence of FAP+ CAFs and targeting the tumor associated antigen
(TAA) named mesothelin. The resultant SMART Dual CAR T-cells
efficiently infiltrate and efficiently target triple-negative
breast tumors in physiologically relevant mice models, with no
observable on-target, off-tumor toxicity.
“The adaptations of this approach could resolve
several key challenges for CAR T-cell therapy against solid
tumor-low CAR T-cell infiltration, immuno-suppressive
microenvironment, antigen heterogeneity as well as on target,
off-tumor toxicity. This strategy thus has significant implications
for successful therapeutic development of CAR T-cells against solid
tumors” said Shipra Das, Ph.D., Associate Director Immuno-Oncology
and Innovation Program Management at Cellectis.
The article is available on Molecular Therapy
website by clicking on this link:
https://www.sciencedirect.com/science/article/pii/S1525001624005409?utm_campaign=STMJ_219742_AUTH_SERV_PA&utm_medium=email&utm_acid=300123771&SIS_ID=&dgcid=STMJ_219742_AUTH_SERV_PA&CMX_ID=&utm_in=DM500444&utm_source=AC_
About
Cellectis Cellectis is a clinical-stage
biotechnology company using its pioneering gene-editing platform to
develop life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with 25
years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“designed to,” and “could” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements include statements about the potential of the research
and development programs of the Company. These forward-looking
statements are made in light of information currently available to
us and are subject to numerous risks and uncertainties, including
with respect to the numerous risks associated with
biopharmaceutical product candidate development. With respect to
our cash runway, our operating plans, including product development
plans, may change as a result of various factors, including factors
currently unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2023 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information on Cellectis, please
contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14
33, media@cellectis.comPatricia Sosa Navarro, Chief of Staff to the
CEO, +33 (0)7 76 77 46 93
Investor Relations
contact: Arthur Stril, Interim Chief Financial
Officer, +1 (347) 809 5980, investors@cellectis.com
- Cellectis Publishes an Article on Dual CAR T(1)
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024